Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Cindy O'Bryant to Humans

This is a "connection" page, showing publications Cindy O'Bryant has written about Humans.

 
Connection Strength
  
 
 
0.251
  
  1. Akce M, El-Khoueiry A, Piha-Paul SA, Bacque E, Pan P, Zhang ZY, Ewesuedo R, Gupta D, Tang Y, Milton A, Zajic S, Judson PL, O'Bryant CL. Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment. Cancer Chemother Pharmacol. 2021 11; 88(5):825-836.
    View in: PubMed
    Score: 0.019
  2. Laird CM, Glode AE, Schwarz K, Lam ET, O'Bryant CL. Evaluation of fosaprepitant-associated hypersensitivity reactions at a National Cancer Center. J Oncol Pharm Pract. 2020 Sep; 26(6):1369-1373.
    View in: PubMed
    Score: 0.017
  3. Jerjian TV, Glode AE, Thompson LA, O'Bryant CL. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy. Pharmacotherapy. 2016 Jan; 36(1):99-116.
    View in: PubMed
    Score: 0.013
  4. Proctor AE, Thompson LA, O'Bryant CL. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma. Ann Pharmacother. 2014 Jan; 48(1):99-106.
    View in: PubMed
    Score: 0.011
  5. O'Bryant CL, Wenger SD, Kim M, Thompson LA. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer. Ann Pharmacother. 2013 Feb; 47(2):189-97.
    View in: PubMed
    Score: 0.011
  6. Kim M, Thompson LA, Wenger SD, O'Bryant CL. Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma. Ann Pharmacother. 2012 Oct; 46(10):1340-8.
    View in: PubMed
    Score: 0.010
  7. Thompson LA, Kim M, Wenger SD, O'Bryant CL. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors. Ann Pharmacother. 2012 Sep; 46(9):1212-9.
    View in: PubMed
    Score: 0.010
  8. O'Bryant CL, Haluska P, Rosen L, Ramanathan RK, Venugopal B, Leong S, Boinpally R, Franke A, Witt K, Evans J, Belani C, Gail Eckhardt S, Ramalingam S. An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer Chemother Pharmacol. 2012 Mar; 69(3):605-12.
    View in: PubMed
    Score: 0.010
  9. Gibson K, O'Bryant CL. Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors. J Oncol Pharm Pract. 2008 Sep; 14(3):139-45.
    View in: PubMed
    Score: 0.008
  10. O'Bryant CL, Crandell BC. Community pharmacists' knowledge of and attitudes toward oral chemotherapy. J Am Pharm Assoc (2003). 2008 Sep-Oct; 48(5):632-9.
    View in: PubMed
    Score: 0.008
  11. O'Bryant CL, Flaig TW, Utz KJ. Bicalutamide-associated fulminant hepatotoxicity. Pharmacotherapy. 2008 Aug; 28(8):1071-5.
    View in: PubMed
    Score: 0.008
  12. O'Bryant CL, Lieu CH, Leong S, Boinpally R, Basche M, Gore L, Leonardi K, Schultz MK, Hariharan S, Chow L, Diab S, Gibbs A, Eckhardt SG. A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state. Cancer Chemother Pharmacol. 2009 Feb; 63(3):477-89.
    View in: PubMed
    Score: 0.008
  13. O'Bryant CL, Linnebur SA, Yamashita TE, Kutner JS. Inconsistencies in opioid equianalgesic ratios: clinical and research implications. J Pain Palliat Care Pharmacother. 2008; 22(4):282-90.
    View in: PubMed
    Score: 0.008
  14. Thompson LE, Ghimire A, Wen X, Kim C, Doherty CL, Buckley BT, Bowles DW, O'Bryant CL, Jaimes EA, Aleksunes LM, Joy MS. Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5-HT3 Antagonist Antiemetic Drugs. J Clin Pharmacol. 2025 Jun; 65(6):763-778.
    View in: PubMed
    Score: 0.006
  15. Miller C, Sommavilla R, O'Bryant CL, Barve M, Dowlati A, Luke JJ, Khatun M, Morris T, Cullberg M. Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2024 Aug; 94(2):223-235.
    View in: PubMed
    Score: 0.006
  16. Schreiber AR, O'Bryant CL, Kabos P, Diamond JR. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan. Expert Rev Anticancer Ther. 2023 Jul-Dec; 23(10):1061-1069.
    View in: PubMed
    Score: 0.006
  17. Davis SL, Ionkina AA, Bagby SM, Orth JD, Gittleman B, Marcus JM, Lam ET, Corr BR, O'Bryant CL, Glode AE, Tan AC, Kim J, Tentler JJ, Capasso A, Lopez KL, Gustafson DL, Messersmith WA, Leong S, Eckhardt SG, Pitts TM, Diamond JR. Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors. Clin Cancer Res. 2020 09 01; 26(17):4633-4642.
    View in: PubMed
    Score: 0.004
  18. Takebe N, Beumer JH, Kummar S, Kiesel BF, Dowlati A, O'Sullivan Coyne G, Piekarz R, Rubinstein L, Fogli LK, Vaishampayan U, Goel S, O'Bryant CL, El-Rayes BF, Chung V, Lenz HJ, Kim R, Belani CP, Tuscano JM, Schelman W, Moore N, Doroshow JH, Chen AP. A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. Br J Clin Pharmacol. 2019 11; 85(11):2499-2511.
    View in: PubMed
    Score: 0.004
  19. Ibrahim ME, Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, O'Bryant CL, Bowles DW, George B, Wen X, Buckley B, Aleksunes L, Joy MS. Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients. Eur J Clin Pharmacol. 2019 Jan; 75(1):51-57.
    View in: PubMed
    Score: 0.004
  20. El-Khoueiry AB, Sarantopoulos J, O'Bryant CL, Ciombor KK, Xu H, O'Gorman M, Chakrabarti J, Usari T, El-Rayes BF. Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer. Cancer Chemother Pharmacol. 2018 04; 81(4):659-670.
    View in: PubMed
    Score: 0.004
  21. Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, Weiss GJ, Chadha M, Oey A, Ding HT, Culp PA, Keller SF, Zhao VY, Tsao LC, Singhal A, Holen KD, Von Hoff D. Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2018 01; 17(1):215-221.
    View in: PubMed
    Score: 0.004
  22. Norman JL, Kroehl ME, Lam HM, Lewis CL, Mitchell CN, O'Bryant CL, Trinkley KE. Implementation of a pharmacist-managed clinic for patients with chronic nonmalignant pain. Am J Health Syst Pharm. 2017 Aug 15; 74(16):1229-1235.
    View in: PubMed
    Score: 0.004
  23. Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, O'Bryant C, Bowles DW, George B, Wen X, Aleksunes LM, Joy MS. Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin. Int J Mol Sci. 2017 Jun 22; 18(7).
    View in: PubMed
    Score: 0.004
  24. Nightingale G, Saunders IM, Comeau JM, Fancher K, Miller T, O'Bryant C, Yeh J. Hematology/Oncology Pharmacy Association Entry-level Competencies Task Force Response Statement to the 2016 American College of Clinical Pharmacy Pharmacotherapy Didactic Curriculum Toolkit. Pharmacotherapy. 2017 05; 37(5):e30-e31.
    View in: PubMed
    Score: 0.004
  25. Dheeraj A, Rigby CM, O'Bryant CL, Agarwal C, Singh RP, Deep G, Agarwal R. Silibinin Treatment Inhibits the Growth of Hedgehog Inhibitor-Resistant Basal Cell Carcinoma Cells via Targeting EGFR-MAPK-Akt and Hedgehog Signaling. Photochem Photobiol. 2017 07; 93(4):999-1007.
    View in: PubMed
    Score: 0.004
  26. George B, Wen X, Mercke N, Gomez M, O'Bryant C, Bowles DW, Hu Y, Hogan SL, Joy MS, Aleksunes LM. Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time-dependent Changes in the Absence of Clinical Nephrotoxicity. Clin Pharmacol Ther. 2017 04; 101(4):510-518.
    View in: PubMed
    Score: 0.004
  27. Page RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2016 Aug 09; 134(6):e32-69.
    View in: PubMed
    Score: 0.003
  28. Ignoffo R, Knapp K, Barnett M, Barbour SY, D'Amato S, Iacovelli L, Knudsen J, Koontz SE, Mancini R, McBride A, McCauley D, Medina P, O'Bryant CL, Scarpace S, Stricker S, Trovato JA. Board-Certified Oncology Pharmacists: Their Potential Contribution to Reducing a Shortfall in Oncology Patient Visits. J Oncol Pract. 2016 Apr; 12(4):e359-68.
    View in: PubMed
    Score: 0.003
  29. Jones RL, Bendell JC, Smith DC, Diefenbach K, Lettieri J, Boix O, Lockhart AC, O'Bryant C, Moore KN. A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2015 Oct; 76(4):777-84.
    View in: PubMed
    Score: 0.003
  30. Wong KM, Noonan S, O'Bryant C, Jimeno A. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer. Drugs Today (Barc). 2015 Mar; 51(3):161-70.
    View in: PubMed
    Score: 0.003
  31. Ragucci KR, O'Bryant CL, Campbell KB, Buck ML, Dager WE, Donovan JL, Emerson K, Gubbins PO, Haight RJ, Jackevicius C, Murphy JE, Prohaska E. The need for PGY2-trained clinical pharmacy specialists. Pharmacotherapy. 2014 Jun; 34(6):e65-73.
    View in: PubMed
    Score: 0.003
  32. Thompson LA, Saseen JJ, O'Bryant CL, Allen RR, Nair KV. Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors. J Oncol Pharm Pract. 2015 Aug; 21(4):258-67.
    View in: PubMed
    Score: 0.003
  33. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno A. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2012 Aug 01; 18(15):4173-82.
    View in: PubMed
    Score: 0.003
  34. Bowles DW, O'Bryant CL, Camidge DR, Jimeno A. The intersection between cannabis and cancer in the United States. Crit Rev Oncol Hematol. 2012 Jul; 83(1):1-10.
    View in: PubMed
    Score: 0.002
  35. Gore L, Rivera E, Basche M, Moulder-Thompson SL, Li J, Eppers S, Grolnic S, O'Bryant C, Cleere D, Elsayed YA, Eckhardt SG. Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies. Invest New Drugs. 2012 Oct; 30(5):1942-9.
    View in: PubMed
    Score: 0.002
  36. Zerzan J, Benton K, Linnebur S, O'Bryant C, Kutner J. Variation in pain medication use in end-of-life care. J Palliat Med. 2010 May; 13(5):501-4.
    View in: PubMed
    Score: 0.002
  37. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010 Feb 10; 28(5):780-7.
    View in: PubMed
    Score: 0.002
  38. Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, Gore L, Smith M, Chow LQ, von Mehren M, O'Bryant C, Hariharan S, Diab S, Fox NL, Miceli R, Eckhardt SG. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol. 2009 Sep 10; 27(26):4413-21.
    View in: PubMed
    Score: 0.002
  39. Lam ET, O'Bryant CL, Basche M, Gustafson DL, Serkova N, Baron A, Holden SN, Dancey J, Eckhardt SG, Gore L. A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors. Mol Cancer Ther. 2008 Dec; 7(12):3685-94.
    View in: PubMed
    Score: 0.002
  40. Lieu C, Chow L, Pierson AS, Eckhardt SG, O'Bryant CL, Morrow M, Tran ZV, Wright JJ, Gore L. A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy. Invest New Drugs. 2009 Feb; 27(1):53-62.
    View in: PubMed
    Score: 0.002
  41. Gore L, Rothenberg ML, O'Bryant CL, Schultz MK, Sandler AB, Coffin D, McCoy C, Schott A, Scholz C, Eckhardt SG. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res. 2008 Jul 15; 14(14):4517-25.
    View in: PubMed
    Score: 0.002
  42. Chow LQ, Gustafson DL, O'Bryant CL, Gore L, Basche M, Holden SN, Morrow MC, Grolnic S, Creese BR, Roberts KL, Davis K, Addison R, Eckhardt SG. A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies. Cancer Chemother Pharmacol. 2008 Dec; 63(1):65-74.
    View in: PubMed
    Score: 0.002
  43. Camidge DR, Gail Eckhardt S, Gore L, O'Bryant CL, Leong S, Basche M, Holden SN, Musib L, Baldwin J, Darstein C, Thornton D, Finn RS, Britten CD. A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors. Anticancer Drugs. 2008 Jan; 19(1):77-84.
    View in: PubMed
    Score: 0.002
  44. Chow LQ, Eckhardt SG, O'Bryant CL, Schultz MK, Morrow M, Grolnic S, Basche M, Gore L. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008 Sep; 62(4):631-46.
    View in: PubMed
    Score: 0.002
  45. Hariharan S, Gustafson D, Holden S, McConkey D, Davis D, Morrow M, Basche M, Gore L, Zang C, O'Bryant CL, Baron A, Gallemann D, Colevas D, Eckhardt SG. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol. 2007 Aug; 18(8):1400-7.
    View in: PubMed
    Score: 0.002
  46. Chiappori AA, Eckhardt SG, Bukowski R, Sullivan DM, Ikeda M, Yano Y, Yamada-Sawada T, Kambayashi Y, Tanaka K, Javle MM, Mekhail T, O'bryant CL, Creaven PJ. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res. 2007 Apr 01; 13(7):2091-9.
    View in: PubMed
    Score: 0.002
  47. Gore L, Holden SN, Cohen RB, Morrow M, Pierson AS, O'Bryant CL, Persky M, Gustafson D, Mikule C, Zhang S, Palmer PA, Eckhardt SG. A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors. Ann Oncol. 2006 Nov; 17(11):1709-17.
    View in: PubMed
    Score: 0.002
  48. Basche M, Gustafson DL, Holden SN, O'Bryant CL, Gore L, Witta S, Schultz MK, Morrow M, Levin A, Creese BR, Kangas M, Roberts K, Nguyen T, Davis K, Addison RS, Moore JC, Eckhardt SG. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res. 2006 Sep 15; 12(18):5471-80.
    View in: PubMed
    Score: 0.002
  49. Kobayashi H, Eckhardt SG, Lockridge JA, Rothenberg ML, Sandler AB, O'Bryant CL, Cooper W, Holden SN, Aitchison RD, Usman N, Wolin M, Basche ML. Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2005 Oct; 56(4):329-36.
    View in: PubMed
    Score: 0.002
  50. Witta SE, Gustafson DL, Pierson AS, Menter A, Holden SN, Basche M, Persky M, O'Bryant CL, Zeng C, Baron A, Long ME, Gibbs A, Kelly K, Bunn PA, Chan DC, Pallansch P, Eckhardt SG. A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors. Clin Cancer Res. 2004 Nov 01; 10(21):7229-37.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)